Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
$8.01
-1.8%		$7.18
$5.25
▼
$9.32
$530.55M1.07526,841 shs1.31 million shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$29.08
+0.1%		$28.83
$5.21
▼
$30.39
$145.37M0.44112,909 shs712,400 shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.60
-4.8%		$1.68
$1.30
▼
$3.48
$507.90M1.71.58 million shs2.16 million shs
VectivBio Holding AG stock logo
VECT
VectivBio
$16.85
$16.85
$4.25
▼
$16.98
N/AN/AN/AN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-1.84%-6.64%+7.81%+21.57%+43.29%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.00%0.00%0.00%0.00%+299.45%
ProKidney Corp. stock logo
PROK
ProKidney
-4.76%-16.23%-8.05%-12.57%-41.18%
VectivBio Holding AG stock logo
VECT
VectivBio
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
$8.01
-1.8%		$7.18
$5.25
▼
$9.32
$530.55M1.07526,841 shs1.31 million shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$29.08
+0.1%		$28.83
$5.21
▼
$30.39
$145.37M0.44112,909 shs712,400 shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.60
-4.8%		$1.68
$1.30
▼
$3.48
$507.90M1.71.58 million shs2.16 million shs
VectivBio Holding AG stock logo
VECT
VectivBio
$16.85
$16.85
$4.25
▼
$16.98
N/AN/AN/AN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-1.84%-6.64%+7.81%+21.57%+43.29%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.00%0.00%0.00%0.00%+299.45%
ProKidney Corp. stock logo
PROK
ProKidney
-4.76%-16.23%-8.05%-12.57%-41.18%
VectivBio Holding AG stock logo
VECT
VectivBio
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
2.90
Moderate Buy$17.80122.22% Upside
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
1.88
Reduce$30.755.74% Upside
ProKidney Corp. stock logo
PROK
ProKidney
2.67
Moderate Buy$12.00650.00% Upside
VectivBio Holding AG stock logo
VECT
VectivBio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MRSN, VECT, EPRX, and PROK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$25.00
9/24/2026
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$17.00
7/17/2026
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/15/2026
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
7/10/2026
ProKidney Corp. stock logo
PROK
ProKidney
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/AN/AN/AN/A$1.41 per shareN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$33.18M4.38N/AN/A($1.92) per share-15.15
ProKidney Corp. stock logo
PROK
ProKidney
$890K543.50N/AN/A($3.36) per share-0.48
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$38.58M-$1.02N/AN/AN/AN/A-63.97%-43.32%11/3/2026 (Estimated)
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$69.19M-$13.88N/AN/AN/A-211.21%N/A-65.42%N/A
ProKidney Corp. stock logo
PROK
ProKidney
-$68.99M-$0.55N/AN/AN/A-10,288.39%N/A-27.39%11/9/2026 (Estimated)
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest MRSN, VECT, EPRX, and PROK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$0.25-$0.23+$0.02-$0.23N/AN/A
8/10/2026Q2 2026
ProKidney Corp. stock logo
PROK
ProKidney
-$0.14-$0.15-$0.01-$0.15$0.19 million$0.15 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
0.02
16.00
16.00
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/A
1.39
1.39
ProKidney Corp. stock logo
PROK
ProKidney
N/A
8.36
8.36
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
93.92%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%
VectivBio Holding AG stock logo
VECT
VectivBio
N/A

Insider Ownership

CompanyInsider Ownership
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
13.00%
ProKidney Corp. stock logo
PROK
ProKidney
39.83%
VectivBio Holding AG stock logo
VECT
VectivBio
9.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
4965.02 millionN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
1505.00 million4.35 millionOptionable
ProKidney Corp. stock logo
PROK
ProKidney
231302.32 million181.91 millionOptionable
VectivBio Holding AG stock logo
VECT
VectivBio
30N/AN/ANo Data

Recent News About These Companies

Ironwood Pharma to acquire VectivBio for $1.15 bln
July 12, 2026  |  nasdaq.comhttps://www.nasdaq.com/articles/ironwood-pharma-to-acquire-vectivbio-for-$1.15-bln
VectivBio Announces Pricing of Initial Public Offering
June 16, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2021/04/08/vectivbio-announces-pricing-of-initial-public-offering
What Recent Medicare Pricing Terms Mean For The Ironwood Pharmaceuticals (IRWD) Investment Story
February 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/recent-medicare-pricing-terms-mean-070520006.html
Boston biotech settles lawsuit alleging misappropriation of GLP-2 analog intellectual property
December 23, 2025  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2025/12/23/ironwood-settles-suit-vectivbio.html
Biotech acquired by Ironwood faces allegations of misappropriating trade secrets
November 11, 2025  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2025/11/11/ironwood-vectivbio-lawsuit.html
Ironwood’s shares sink as FDA demands new trial for lead drug
April 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/ironwood-s-shares-sink-as-fda-demands-new-trial-for-lead-drug/ar-AA1CYXei
A brain biotech launches with Roche’s spare parts
February 13, 2025  |  biopharmadive.comB
Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer
January 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/aravax-continues-international-expansion-with-appointment-of-aled-williams-as-chief-business-officer-1034248130
CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer
December 5, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/cdr-life-appoints-sarah-holland-120000030.html
Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD
November 12, 2024  |  gut.bmj.comG
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight
September 23, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/graft-versus-host-disease-market-043000895.html
Etherio Group: 2024 CMI 25
September 21, 2024  |  meetingsnet.comM
Compare with VectivBio Holding AG (VECT)
May 29, 2024  |  msn.comhttps://www.msn.com/en-nz/money/compare?id=c1dbbh
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/engene-announces-election-paul-hastings-200500599.html
Vicore Pharma Holding: Vicore Expands and Strengthens its Board of Directors
May 14, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-05/62220612-vicore-pharma-holding-vicore-expands-and-strengthens-its-board-of-directors-200.htm
Vicore Expands and Strengthens its Board of Directors
May 14, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/vicore-expands-strengthens-board-directors-062000534.html
Short Bowel Syndrome Market by 2032: Forecast Report Estimates Significant Growth
April 5, 2024  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/short-bowel-syndrome-market-2032-114900366.html
FDA approves DMD treatment from Italfarmaco
March 31, 2024  |  cen.acs.orgC
IFLR Europe Awards 2024: shortlist revealed
February 8, 2024  |  iflr.comI
Ironwood seals the deal on VectivBio merger
December 13, 2023  |  msn.comhttps://www.msn.com/en-us/money/companies/ironwood-seals-the-deal-on-vectivbio-merger/ar-AA1lsCRC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eupraxia Pharmaceuticals stock logo

Eupraxia Pharmaceuticals NASDAQ:EPRX

$8.01 -0.15 (-1.84%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$8.01 0.00 (0.00%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Mersana Therapeutics stock logo

Mersana Therapeutics NASDAQ:MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

ProKidney stock logo

ProKidney NASDAQ:PROK

$1.60 -0.08 (-4.76%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$1.64 +0.04 (+2.44%)
As of 09/25/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

VectivBio stock logo

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)
As of 09/25/2026

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas